Xuanzhu Biopharmaceutical Co., Ltd. (HKG:2575)

Market Cap	18.18B
Revenue (ttm)	35.02M +103,672.4%
Net Income	-609.65M
EPS	-1.35
Shares Out	517.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	666,000
Average Volume	989,429
Open	36.12
Previous Close	36.12
Day's Range	35.10 - 37.80
52-Week Range	23.82 - 96.90
Beta	n/a
RSI	27.80
Earnings Date	Mar 30, 2026

About Xuanzhu Biopharmaceutical

Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead product candidates include Core- KBP-3571 for the treatment of duodenum ulcers; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2 advanced breast cancer; and XZP-3621, a first-line treatment for patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. The company also develops KM501, a first-in-class HER2/HER2 bisp...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 197
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2575

Financial Performance

In 2024, Xuanzhu Biopharmaceutical's revenue was 30.09 million, an increase of 103672.41% compared to the previous year's 29,000. Losses were -556.43 million, 85.1% more than in 2023.

Financial numbers in CNY